CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 219 enrolled
Drug / intervention
Mavenclad®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04783935
NCT04783935Phase 4Completed
CompareCT.gov

A 2-year Extension Study to Evaluate Long-term Effectiveness of Mavenclad® in Participants Who Have Completed Trial MS700568_0022 (MAGNIFY MS) (Magnify MS Extension)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany·interventional·Posted Mar 5, 2021·Updated Jan 22, 2025

In Brief

A Phase 4 clinical trial evaluating Mavenclad® for Multiple Sclerosis. Completed, enrolled 219 participants across 46 sites in 14 countries.

Detailed Summary

The primary purpose of this study was to evaluate the long-term effectiveness of Mavenclad® tablets, in terms of disease activity and safety, in participants with highly-active relapsing multiple sclerosis (RMS) previously participating in the MAGNIFY MS trial MS700568\_0022 (NCT03364036).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesAustralia, Austria, Canada, Czechia, Finland, France, Germany, Hungary, Israel, Italy, Poland, Spain, Sweden, United Kingdom
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedMar 5, 2021
Enrollment StartMar 10, 2021
Primary CompletionSep 21, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.3 years ago

Interventions

Mavenclad®drug

No intervention was administered as a part of this study. Participants who had received Mavenclad® up to 2 years (Year 1 and 2) in the parent study MS700568\_0022 (NCT03364036) were enrolled into this extension study and will be assessed up to 2 years follow-up (Year 3 and 4).